Liver–Heart on chip models for drug safety
Current pre-clinical models to evaluate drug safety during the drug development process (DDP) mainly rely on traditional two-dimensional cell cultures, considered too simplistic and often ineffective, or animal experimentations, which are costly, time-consuming, and not truly representative of human...
Main Authors: | Erika Ferrari, Marco Rasponi |
---|---|
Format: | Article |
Language: | English |
Published: |
AIP Publishing LLC
2021-09-01
|
Series: | APL Bioengineering |
Online Access: | http://dx.doi.org/10.1063/5.0048986 |
Similar Items
-
Integrating Biosensors in Organs-on-Chip Devices: A Perspective on Current Strategies to Monitor Microphysiological Systems
by: Erika Ferrari, et al.
Published: (2020-08-01) -
Controlled electromechanical cell stimulation on-a-chip
by: Pavesi, Andrea, et al.
Published: (2015) -
High-Throughput Assessment of Drug Cardiac Safety Using a High-Speed Impedance Detection Technology-Based Heart-on-a-Chip
by: Xi Zhang, et al.
Published: (2016-07-01) -
Microfabricated Physiological Models for In Vitro Drug Screening Applications
by: Giovanni Stefano Ugolini, et al.
Published: (2016-12-01) -
Counterfeit/copy drugs: patients safety in the heart
by: Y. Capan
Published: (2011-12-01)